HER2-positive metastatic breast cancer drug combination study
Part of Cancer clinical trials.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have HER2-positive advanced breast cancer that cannot be removed by radical surgery
- Have test results showing HER2 positivity (IHC 3+ or HER2 gene amplification on another test)
- Be able to do treatment with acceptable heart test results and overall physical functioning (ECOG 0–2)
- Not be pregnant or breastfeeding, and use contraception during treatment and for 6 months after
- No major allergy to these study drug ingredients and no known immune system problems (like HIV)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
This trial tests a new combination of targeted therapies (inetetamab plus rapamycin) with chemotherapy for HER2-positive breast cancer that has spread or come back and has a specific genetic change (PAM pathway mutation). It aims to see if this combination can work better than current treatments for people whose cancer has progressed after trastuzumab.
This study tests a combination of two or three targeted medicines (Inetetamab, Paclitaxel, with or without Pertuzumab) in people with HER2-positive advanced breast cancer. The goal is to see if this new treatment helps shrink tumors and control the disease better than existing options.
Hear when a new HER2-positive Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.